vs
ARTIVION, INC.（AORT）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
Penumbra Inc的季度营收约是ARTIVION, INC.的3.3倍（$385.4M vs $116.0M）。Penumbra Inc净利率更高（12.3% vs 2.1%，领先10.2%）。Penumbra Inc同比增速更快（22.1% vs 19.2%）。Penumbra Inc自由现金流更多（$68.0M vs $-7.9M）。过去两年Penumbra Inc的营收复合增速更高（17.6% vs 9.1%）
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
AORT vs PEN — 直观对比
营收规模更大
PEN
是对方的3.3倍
$116.0M
营收增速更快
PEN
高出2.9%
19.2%
净利率更高
PEN
高出10.2%
2.1%
自由现金流更多
PEN
多$76.0M
$-7.9M
两年增速更快
PEN
近两年复合增速
9.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $116.0M | $385.4M |
| 净利润 | $2.4M | $47.3M |
| 毛利率 | 63.1% | 68.0% |
| 营业利润率 | 9.2% | 15.4% |
| 净利率 | 2.1% | 12.3% |
| 营收同比 | 19.2% | 22.1% |
| 净利润同比 | 114.7% | 40.6% |
| 每股收益（稀释后） | $0.06 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AORTPEN
| Q4 25 | $116.0M | $385.4M | ||
| Q3 25 | $113.4M | $354.7M | ||
| Q2 25 | $113.0M | $339.5M | ||
| Q1 25 | $99.0M | $324.1M | ||
| Q4 24 | $97.3M | $315.5M | ||
| Q3 24 | $95.8M | $301.0M | ||
| Q2 24 | $98.0M | $299.4M | ||
| Q1 24 | $97.4M | $278.7M |
净利润AORTPEN
| Q4 25 | $2.4M | $47.3M | ||
| Q3 25 | $6.5M | $45.9M | ||
| Q2 25 | $1.3M | $45.3M | ||
| Q1 25 | $-505.0K | $39.2M | ||
| Q4 24 | $-16.5M | $33.7M | ||
| Q3 24 | $-2.3M | $29.5M | ||
| Q2 24 | $-2.1M | $-60.2M | ||
| Q1 24 | $7.5M | $11.0M |
毛利率AORTPEN
| Q4 25 | 63.1% | 68.0% | ||
| Q3 25 | 65.6% | 67.8% | ||
| Q2 25 | 64.7% | 66.0% | ||
| Q1 25 | 64.2% | 66.6% | ||
| Q4 24 | 63.2% | 66.8% | ||
| Q3 24 | 63.7% | 66.5% | ||
| Q2 24 | 64.6% | 54.4% | ||
| Q1 24 | 64.6% | 65.0% |
营业利润率AORTPEN
| Q4 25 | 9.2% | 15.4% | ||
| Q3 25 | 11.1% | 13.8% | ||
| Q2 25 | 7.4% | 12.0% | ||
| Q1 25 | 2.2% | 12.4% | ||
| Q4 24 | 2.7% | 13.6% | ||
| Q3 24 | 4.6% | 11.7% | ||
| Q2 24 | 6.6% | -27.0% | ||
| Q1 24 | 26.0% | 4.3% |
净利率AORTPEN
| Q4 25 | 2.1% | 12.3% | ||
| Q3 25 | 5.7% | 12.9% | ||
| Q2 25 | 1.2% | 13.3% | ||
| Q1 25 | -0.5% | 12.1% | ||
| Q4 24 | -16.9% | 10.7% | ||
| Q3 24 | -2.4% | 9.8% | ||
| Q2 24 | -2.2% | -20.1% | ||
| Q1 24 | 7.7% | 3.9% |
每股收益（稀释后）AORTPEN
| Q4 25 | $0.06 | $1.20 | ||
| Q3 25 | $0.13 | $1.17 | ||
| Q2 25 | $0.03 | $1.15 | ||
| Q1 25 | $-0.01 | $1.00 | ||
| Q4 24 | $-0.40 | $0.88 | ||
| Q3 24 | $-0.05 | $0.75 | ||
| Q2 24 | $-0.05 | $-1.55 | ||
| Q1 24 | $0.18 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.9M | $186.9M |
| 总债务越低越好 | $215.1M | — |
| 股东权益账面价值 | $448.2M | $1.4B |
| 总资产 | $884.8M | $1.8B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资AORTPEN
| Q4 25 | $64.9M | $186.9M | ||
| Q3 25 | $73.4M | $321.0M | ||
| Q2 25 | $53.5M | $421.8M | ||
| Q1 25 | $37.7M | $376.1M | ||
| Q4 24 | $53.5M | $324.4M | ||
| Q3 24 | $56.2M | $280.5M | ||
| Q2 24 | $55.0M | $288.3M | ||
| Q1 24 | $51.1M | $223.1M |
总债务AORTPEN
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — | ||
| Q1 24 | $313.3M | — |
股东权益AORTPEN
| Q4 25 | $448.2M | $1.4B | ||
| Q3 25 | $438.7M | $1.4B | ||
| Q2 25 | $419.9M | $1.3B | ||
| Q1 25 | $294.3M | $1.2B | ||
| Q4 24 | $276.2M | $1.2B | ||
| Q3 24 | $304.7M | $1.1B | ||
| Q2 24 | $295.1M | $1.2B | ||
| Q1 24 | $295.0M | $1.2B |
总资产AORTPEN
| Q4 25 | $884.8M | $1.8B | ||
| Q3 25 | $857.7M | $1.7B | ||
| Q2 25 | $838.4M | $1.7B | ||
| Q1 25 | $791.2M | $1.6B | ||
| Q4 24 | $789.1M | $1.5B | ||
| Q3 24 | $803.1M | $1.5B | ||
| Q2 24 | $789.5M | $1.5B | ||
| Q1 24 | $784.0M | $1.6B |
负债/权益比AORTPEN
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.6M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $-7.9M | $68.0M |
| 自由现金流率自由现金流/营收 | -6.9% | 17.7% |
| 资本支出强度资本支出/营收 | 23.7% | 4.8% |
| 现金转化率经营现金流/净利润 | 8.06× | 1.83× |
| 过去12个月自由现金流最近4个季度 | $839.0K | $174.9M |
8季度趋势，按日历期对齐
经营现金流AORTPEN
| Q4 25 | $19.6M | $86.5M | ||
| Q3 25 | $22.3M | $58.3M | ||
| Q2 25 | $15.0M | $44.9M | ||
| Q1 25 | $-17.0M | $49.0M | ||
| Q4 24 | $10.1M | $51.1M | ||
| Q3 24 | $11.5M | $56.5M | ||
| Q2 24 | $6.1M | $22.6M | ||
| Q1 24 | $-5.5M | $38.3M |
自由现金流AORTPEN
| Q4 25 | $-7.9M | $68.0M | ||
| Q3 25 | $17.7M | $42.0M | ||
| Q2 25 | $11.7M | $29.4M | ||
| Q1 25 | $-20.6M | $35.5M | ||
| Q4 24 | $8.7M | $45.7M | ||
| Q3 24 | $7.8M | $51.0M | ||
| Q2 24 | $3.6M | $18.1M | ||
| Q1 24 | $-9.1M | $32.5M |
自由现金流率AORTPEN
| Q4 25 | -6.9% | 17.7% | ||
| Q3 25 | 15.6% | 11.8% | ||
| Q2 25 | 10.4% | 8.7% | ||
| Q1 25 | -20.8% | 11.0% | ||
| Q4 24 | 9.0% | 14.5% | ||
| Q3 24 | 8.2% | 16.9% | ||
| Q2 24 | 3.7% | 6.0% | ||
| Q1 24 | -9.3% | 11.7% |
资本支出强度AORTPEN
| Q4 25 | 23.7% | 4.8% | ||
| Q3 25 | 4.1% | 4.6% | ||
| Q2 25 | 2.9% | 4.6% | ||
| Q1 25 | 3.7% | 4.2% | ||
| Q4 24 | 1.5% | 1.7% | ||
| Q3 24 | 3.8% | 1.8% | ||
| Q2 24 | 2.6% | 1.5% | ||
| Q1 24 | 3.7% | 2.1% |
现金转化率AORTPEN
| Q4 25 | 8.06× | 1.83× | ||
| Q3 25 | 3.42× | 1.27× | ||
| Q2 25 | 11.16× | 0.99× | ||
| Q1 25 | — | 1.25× | ||
| Q4 24 | — | 1.52× | ||
| Q3 24 | — | 1.91× | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.73× | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
PEN
暂无分部数据
